A Prospective Open-label Study Evaluating Retinal Nerve Fibre Layer (RNFL) Thickness In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With Alemtuzumab.

Trial Profile

A Prospective Open-label Study Evaluating Retinal Nerve Fibre Layer (RNFL) Thickness In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With Alemtuzumab.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Sep 2016 Results of this study, presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 02 May 2016 New trial record
    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top